TNF alpha antibody (Tumor Necrosis Factor alpha) Primary Antibody
- TNF alpha
- Antibody Type
- Recombinant Antibody
- This TNF alpha antibody is un-conjugated
- Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
- The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive.
- "The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive."
"This is a dimeric fusion protein derived from Enbrel and designed for research purposes. Etanercept, the active ingredient of Enbrel, is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF." Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55- kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.
TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life.
- The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml. (original drug Enbrel 50 was diluted 1:50)
anti-Tumor Necrosis Factor alpha (TNF alpha) (AA 181-235) antibody Primary Antibody
TNF alpha Reactivity: Human, Mouse, Rat, Horse, Rabbit ELISA, ICC, IF (cc), IF (p), IHC (fro), IHC (p), WB Host: Rabbit Polyclonal unconjugated
- Application Notes
- Optimal dilution for a specific application should be determined by user
Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. This Fc component contains the hinge, CH2and CH3regions, but not the CH1region of IgG1. Etanercept contains 934amino acids and has an apparent molecular weight of approximately 150 kilodaltons. The specific activity of etanercept is 1.7x 106units/mg.
- Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
- For Research Use only
- 1 mg/mL
- The dilutant is sterile PBS pH 7.4. No preservatives added
- Without preservative
- Handling Advice
- open only under sterile conditions
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
- Expiry Date
- 48 months
- TNF alpha
- Alternative Name
- TNF-alpha (TNF alpha Antibody Abstract)
- DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin, tumor necrosis factor, tumor necrosis factor b (TNF superfamily, member 2), tumor necrosis factor alpha, tumor necrosis factor a (TNF superfamily, member 2), TNF, Tnf, tnf, tnfb, tnf-alpha, LOC103694380, tnfa
- Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
- Molecular Weight
- 26 kDa
- Gene ID
- NCBI Accession
- NF-kappaB Signaling, Apoptosis, Caspase Cascade in Apoptosis, TLR Signaling, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Inflammasome